Introduction

Zepbound (tirzepatide) has become one of the most commercially important medicines in the obesity treatment market, while its clinical profile is expanding beyond weight reduction alone. Developed by Eli Lilly and Company, Zepbound is a once-weekly injectable therapy that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In the United States, it is approved for chronic weight management in adults with obesity or overweight accompanied by at least one weight-related condition, and for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

The product's importance is not based solely on the amount of weight reduction observed in clinical trials. Zepbound is part of a broader shift in how obesity is being treated as a chronic disease requiring sustained management rather than a short-term intervention. This has implications for pharmaceutical commercialization, payer coverage, primary care, obesity medicine, sleep medicine, manufacturing capacity, and competition among incretin-based therapies.

Recent developments have strengthened that position. In 2025, the SURMOUNT-5 trial directly compared tirzepatide with semaglutide and found greater average weight reduction with tirzepatide in adults with obesity without type 2 diabetes. In 2026, new maintenance data examined whether patients could preserve weight reduction after moving from higher-dose tirzepatide to a lower maintenance dose. At the same time, the U.S. reimbursement environment changed through the launch of the Medicare GLP-1 Bridge, which includes Zepbound KwikPen for eligible beneficiaries seeking weight-management treatment.

For the healthcare market, the significance extends beyond one product. Zepbound illustrates how successful obesity medicines can create demand across pharmaceutical manufacturing, specialty care, digital health, diagnostics, insurance, pharmacy distribution, and long-term disease-management services. It also shows the challenges of scaling access to expensive chronic therapies while maintaining affordability, supply reliability, and appropriate clinical use.

What Is Zepbound?

Zepbound is the brand name used by Eli Lilly for tirzepatide in obesity-related indications in the United States, Canada, and Japan. Tirzepatide is also marketed as Mounjaro for type 2 diabetes in the United States and other markets.

The molecule is a dual GIP and GLP-1 receptor agonist. Both GIP and GLP-1 are incretin hormones involved in metabolic regulation. Tirzepatide influences appetite and food intake through effects on these pathways and also affects glucose-dependent insulin secretion and glucagon regulation.

For weight management, the U.S. Food and Drug Administration approved Zepbound in November 2023 for adults with obesity or adults with overweight and at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. In December 2024, the FDA expanded Zepbound's role by approving it for moderate-to-severe OSA in adults with obesity.

The current U.S. prescribing information, revised in August 2026, lists Zepbound for two indications: long-term reduction and maintenance of excess body weight in eligible adults, and treatment of moderate-to-severe OSA in adults with obesity. For weight reduction and maintenance, the labeled maintenance doses are 5 mg, 10 mg, or 15 mg once weekly. For OSA, the maintenance doses are 10 mg or 15 mg once weekly, with a maximum recommended dose of 15 mg.

The product is available in multiple strengths and delivery formats, including single-dose presentations and the multi-dose KwikPen. The introduction of the KwikPen is commercially relevant because the delivery system provides another route for Lilly to address convenience, distribution, and cash-pay access.

Zepbound is not approved for children in the United States. The label also states that coadministration with other tirzepatide-containing products or GLP-1 receptor agonists is not recommended.

Its safety profile is consistent with the broader class of incretin therapies. Common adverse reactions include gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia. The prescribing information also contains warnings and precautions covering severe gastrointestinal reactions, gallbladder disease, pancreatitis, acute kidney injury, hypersensitivity reactions, hypoglycemia in relevant treatment combinations, diabetic retinopathy complications in patients with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation.

The boxed warning concerns thyroid C-cell tumors observed in rats. The relevance to humans remains unknown, and Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.

Recent Developments and Trends

Zepbound gains a second FDA-approved indication

The FDA's December 2024 approval of Zepbound for moderate-to-severe OSA in adults with obesity was an important expansion of the product's commercial and clinical scope. The decision followed two Phase 3 SURMOUNT-OSA trials involving adults with obesity and moderate-to-severe OSA.

The development is notable because OSA has traditionally been managed through approaches such as positive airway pressure devices, oral appliances, surgery, and behavioral or weight-management interventions. Zepbound introduced a pharmacological option specifically for adults with obesity and moderate-to-severe OSA.

The approval also creates a bridge between two healthcare markets that were previously more distinct: obesity treatment and sleep medicine. This may affect referral patterns, diagnostic pathways, sleep-clinic workflows, and payer discussions around the treatment of obesity-associated OSA.

Tirzepatide demonstrated an advantage over semaglutide in SURMOUNT-5

One of the most closely watched developments was the publication of SURMOUNT-5 in the New England Journal of Medicine in 2025.

The Phase 3b trial enrolled 751 adults with obesity without type 2 diabetes and compared maximum tolerated doses of tirzepatide with semaglutide over 72 weeks. Average body-weight reduction was 20.2% with tirzepatide compared with 13.7% with semaglutide. Tirzepatide also produced a greater reduction in waist circumference.

The results matter commercially because semaglutide has established itself as one of the principal competitors in the medical obesity market. A direct head-to-head study provides a stronger basis for competitive positioning than comparisons across separate clinical trials.

The trial does not mean that every patient will experience the same degree of weight reduction, nor does it eliminate the importance of tolerability, access, reimbursement, dosing, patient preference, and continuity of treatment. From a market perspective, though, the findings strengthen tirzepatide's position in the premium end of the obesity pharmacotherapy segment.

New evidence focuses on long-term weight maintenance

The obesity medicine market is increasingly shifting from the question of how much weight a patient can lose to how effectively that weight can be maintained.

In May 2026, Lilly reported results from SURMOUNT-MAINTAIN. Participants had initially received maximum tolerated doses of Zepbound for 60 weeks and were subsequently assigned to continue at their maximum tolerated dose, reduce treatment to 5 mg, or receive placebo. Those who continued maximum tolerated dosing preserved their previous weight loss on average, while participants reduced to 5 mg maintained most, but not all, of the prior reduction.

The findings are commercially important because long-term maintenance affects the economics of obesity treatment. If obesity is managed as a chronic condition, manufacturers, payers, providers, and patients must consider treatment duration rather than a finite course of therapy.

Maintenance strategies may also create opportunities for more individualized treatment pathways, although decisions about dose changes remain clinical matters rather than a simple commercial strategy.

Manufacturing capacity has become a strategic priority

The rapid adoption of tirzepatide has made manufacturing capacity a central issue for Lilly.

Lilly reported that Zepbound U.S. revenue reached approximately $4.1 billion in the first quarter of 2026 and $4.9 billion in the second quarter. Q2 U.S. Zepbound revenue increased 44% from the prior-year quarter, according to the company, with strong demand partly offset by lower realized prices.

The company has also continued investing in manufacturing infrastructure. In August 2026, Lilly announced an additional $4.5 billion commitment to expand Indiana manufacturing sites. Although the investment supports Lilly's broader portfolio rather than Zepbound alone, it illustrates the capital requirements associated with scaling incretin medicines.

For the market, production capacity is becoming almost as important as clinical differentiation. A medicine with strong demand must be manufactured, packaged, distributed, and reimbursed at a scale that can support chronic treatment.

The U.S. regulatory environment around compounded tirzepatide has changed

Tirzepatide's early supply constraints contributed to a large compounding market. The FDA determined in October 2024 that the tirzepatide injection shortage had been resolved, later reevaluated the issue, and again determined the shortage resolved in December 2024.

By 2026, the FDA was clarifying policies for compounders as national GLP-1 supply stabilized. The agency emphasized statutory restrictions concerning compounded products that are essentially copies of commercially available FDA-approved medicines.

This has implications for manufacturers, pharmacies, telehealth companies, and consumers. As commercially manufactured supply becomes more accessible, the regulatory basis for widespread compounding of essentially equivalent tirzepatide products becomes narrower.

Medicare GLP-1 access has entered a new phase

A major 2026 development is the Medicare GLP-1 Bridge, launched by the Centers for Medicare & Medicaid Services on July 1, 2026.

The temporary demonstration provides eligible Medicare Part D beneficiaries access to certain GLP-1 medicines for weight management at a $50 monthly copay. Zepbound KwikPen is among the eligible products. The demonstration is scheduled to operate through December 31, 2027.

This is an important market development because Medicare historically has faced statutory limitations around coverage of weight-loss drugs. The Bridge creates a new mechanism for testing utilization, affordability, prior authorization, and healthcare-system effects associated with broader access to GLP-1 medicines.

The program is not equivalent to universal Medicare coverage of obesity medicines. Eligibility criteria apply, and the demonstration operates outside the standard Part D payment flow.

Impact on the Healthcare Industry

Zepbound's impact extends beyond obesity specialists

Patients and providers

The product expands pharmacological options for adults managing obesity and, through its OSA indication, gives some patients an alternative to relying exclusively on existing sleep-apnea interventions.

For clinicians, the growth of incretin-based treatment creates new demands around patient selection, monitoring, adverse-event management, treatment persistence, and coordination between specialties. Primary care physicians may increasingly encounter obesity pharmacotherapy as part of routine chronic disease management, while endocrinologists, obesity specialists, cardiologists, gastroenterologists, and sleep specialists may all interact with patients receiving tirzepatide.

Pharmaceutical and biotechnology companies

Zepbound has raised the competitive standard for obesity medicines. Drug developers are now competing not only on weight reduction but also on dosing convenience, route of administration, tolerability, durability, comorbidity outcomes, and affordability.

The market is consequently expanding from injectable GLP-1 receptor agonists toward other incretin combinations, oral therapies, and next-generation molecules.

Lilly itself is pursuing a broader cardiometabolic portfolio. Its pipeline includes retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, while orforglipron represents an oral GLP-1 approach. These programs are not replacements for Zepbound today, but they show how the commercial strategy is evolving beyond a single injectable product. 

Healthcare delivery

The scale of obesity pharmacotherapy could alter how weight management is delivered. Instead of isolated prescriptions, healthcare systems may increasingly integrate medication management with nutritional counseling, behavioral support, laboratory monitoring, sleep evaluation, and management of obesity-related diseases.

This creates opportunities for digital-health platforms, remote patient monitoring, pharmacy services, nutrition providers, and clinical decision-support tools.

At the same time, increased demand can place pressure on primary care capacity. Health systems that expand obesity treatment programs may need standardized workflows for eligibility assessment, follow-up, adverse-event management, and insurance authorization.

Sleep medicine

Zepbound's OSA indication has particular implications for sleep medicine. OSA diagnosis frequently requires specialized testing, and treatment can involve durable medical equipment such as positive airway pressure systems.

A pharmacological option does not eliminate the need for diagnosis or individualized treatment selection. Instead, it introduces another treatment category that sleep physicians and payers must evaluate alongside established approaches.

Market and Business Implications

Zepbound provides a useful example of how a pharmaceutical product can reshape an entire healthcare market.

Demand is moving toward chronic obesity management

Lilly's reported sales illustrate the scale of commercial adoption. Zepbound generated $13.5 billion in worldwide revenue in 2025, compared with $4.9 billion in 2024. In the first half of 2026, U.S. sales were approximately $9.1 billion based on Lilly's first- and second-quarter reports.

These figures demonstrate that obesity pharmacotherapy is no longer a niche pharmaceutical segment. It has become a major commercial category with consequences for manufacturing investment, payer negotiations, pharmacy distribution, and competitive R&D.

The market should nevertheless be interpreted carefully. High prescription demand does not automatically translate into sustained treatment persistence, universal insurance coverage, or equivalent access across populations.

Pricing and reimbursement are becoming competitive tools

As multiple incretin products compete for patients, price is becoming an important component of commercialization.

Lilly has introduced cash-pay pricing initiatives and multiple Zepbound delivery options. At the same time, CMS's Medicare GLP-1 Bridge introduces a $50 monthly copay for eligible beneficiaries receiving covered products through the demonstration.

This creates a more complex pricing environment involving list prices, negotiated prices, rebates, cash-pay programs, employer benefits, Medicare demonstrations, and commercial insurance policies.

For pharmaceutical market analysts, headline list prices therefore provide an incomplete picture of the commercial environment. Realized prices, access restrictions, patient assistance, and payer mix increasingly influence revenue and market penetration.

Competition is broadening

Zepbound competes directly with semaglutide-based obesity products, particularly Wegovy, while other companies are developing oral GLP-1 medicines and next-generation incretin therapies.

The competitive question is also moving beyond percentage weight loss. Products may differentiate through oral administration, dosing frequency, maintenance strategies, cardiovascular or metabolic outcomes, tolerability, manufacturing scalability, and total treatment cost.

Lilly's own development of orforglipron and retatrutide demonstrates the strategic importance of maintaining a portfolio across multiple treatment formats and generations.

Manufacturing is a competitive capability

The obesity market has demonstrated that demand can outpace conventional pharmaceutical supply planning. For manufacturers, investments in peptide production, fill-finish capacity, injection devices, packaging, quality control, and distribution are therefore strategic rather than simply operational.

The companies capable of scaling production reliably may have an advantage even when competing products demonstrate comparable clinical efficacy.

Healthcare services may develop around GLP-1 treatment

The expansion of obesity pharmacotherapy is creating opportunities outside the drug market itself. Employers, insurers, telehealth companies, pharmacies, obesity clinics, nutrition providers, and digital health platforms can build services around medication access and long-term disease management.

The strongest opportunities are likely to be those that address measurable healthcare needs such as improving persistence, coordinating clinical follow-up, supporting appropriate prescribing, or reducing administrative friction rather than simply facilitating prescriptions.

Key Companies and Industry Participants

Eli Lilly and Company

Eli Lilly is the primary company behind tirzepatide and controls the Zepbound franchise in its relevant markets. Its strategy extends from commercialization to manufacturing expansion and development of next-generation obesity medicines.

Zepbound's sales growth has become a major contributor to Lilly's overall financial performance, giving the company substantial resources and incentives to expand cardiometabolic manufacturing and R&D.

Novo Nordisk

Novo Nordisk is the principal pharmaceutical competitor in the obesity incretin market through semaglutide-based products such as Wegovy. The SURMOUNT-5 head-to-head comparison with semaglutide makes Novo Nordisk particularly relevant to Zepbound's competitive positioning.

The rivalry between tirzepatide and semaglutide is influencing the broader development strategy of the obesity pharmaceutical industry.

U.S. Food and Drug Administration

The FDA remains central to Zepbound's market status through its approvals, prescribing information, safety monitoring, and policies concerning compounded tirzepatide.

The agency's evolving approach to supply and compounding also demonstrates how regulatory decisions can influence the commercial structure of a pharmaceutical market.

Centers for Medicare & Medicaid Services

CMS has become an increasingly important stakeholder following the launch of the Medicare GLP-1 Bridge. Its demonstration could generate additional evidence on utilization, access, affordability, and spending associated with obesity pharmacotherapy.

Healthcare providers and payers

Providers, commercial insurers, Medicare plans, employers, pharmacies, and health systems collectively determine how accessible Zepbound becomes in practice. Their decisions influence prior authorization, patient selection, treatment continuity, and total healthcare spending.

Challenges and Limitations

Zepbound's commercial success does not remove the structural challenges associated with obesity pharmacotherapy.

Long-term treatment remains a central issue. Obesity is a chronic disease, and maintaining weight reduction may require continued pharmacological treatment. This creates uncertainty for patients and payers around treatment duration and cumulative cost.

Affordability remains uneven. Even as cash-pay programs and public initiatives expand access, coverage differs considerably among employers, insurers, government programs, and geographic markets.

Adverse effects can affect persistence. Gastrointestinal reactions are common, particularly during treatment escalation. For manufacturers and healthcare providers, tolerability can influence discontinuation and therefore real-world effectiveness.

Supply chains remain strategically important. Although the FDA determined the tirzepatide shortage resolved, rapid demand growth creates ongoing requirements for manufacturing capacity and distribution resilience. Local pharmacy availability can differ even when national supply is adequate.

Regulatory scrutiny of compounded products is likely to remain relevant. As branded supply improves, the distinction between FDA-approved products and compounded versions becomes more important for quality, regulatory compliance, and market competition.

Clinical evidence is still expanding. Tirzepatide has produced encouraging findings in areas such as MASH and heart failure with preserved ejection fraction, but those research findings should not automatically be treated as approved Zepbound indications. Lilly's SURMOUNT-MMO trial is also evaluating cardiovascular morbidity and mortality in adults with obesity, with completion expected after 2026.

The market may become more fragmented. As oral therapies and next-generation incretin combinations reach advanced development stages, companies may compete across several dimensions simultaneously. This could increase choice while also making treatment selection and payer management more complex.

Future Outlook

The future of Zepbound is likely to be shaped by three interconnected factors: evidence, access, and competition.

Clinical research will remain important. Tirzepatide has already generated evidence across obesity, OSA, heart failure with preserved ejection fraction, and MASH, while additional studies are examining cardiovascular outcomes, chronic kidney disease, maintenance strategies, and other obesity-related conditions. The distinction between established evidence and future indications will remain important as the molecule's clinical profile expands.

The SURMOUNT-MMO cardiovascular outcomes trial is particularly relevant from a market perspective. It is evaluating whether tirzepatide affects a composite of major cardiovascular and heart-failure outcomes in adults with obesity. A large outcomes trial could provide information that influences payer assessments and the positioning of obesity treatment within broader cardiometabolic care.

The competitive environment is also likely to become more sophisticated. Semaglutide remains an established alternative, while Lilly's orforglipron and retatrutide programs illustrate the next stage of competition. Oral administration could address a different set of patient preferences and healthcare-delivery requirements, while higher-efficacy multi-receptor therapies could create another competitive tier.

Manufacturing will remain a defining commercial capability. Lilly's continued investment in production infrastructure suggests that the company expects sustained demand for incretin-based medicines. Competitors face similar challenges as they attempt to scale their own products.

Reimbursement could become one of the largest determinants of market expansion. The Medicare GLP-1 Bridge provides an important real-world test of what happens when eligible Medicare beneficiaries gain structured access to obesity medicines at a predictable monthly copay. Data from the demonstration could inform future policy discussions around obesity-drug coverage.

For healthcare organizations, the longer-term opportunity is likely to involve integrated obesity management rather than medication alone. Providers and payers may increasingly evaluate these medicines in terms of downstream healthcare utilization, comorbidity management, treatment persistence, and total cost of care.

Conclusion

Zepbound has moved from being a new obesity medicine to becoming a major component of the global incretin market. Its dual GIP and GLP-1 mechanism, strong weight-loss results, FDA approval for obesity and OSA, and expanding clinical evidence have given tirzepatide a broad role in cardiometabolic medicine.

The 2025 SURMOUNT-5 results strengthened Zepbound's competitive position against semaglutide, while 2026 maintenance data added evidence around longer-term treatment strategies. Commercially, Lilly's reported sales and continued manufacturing investments demonstrate the scale of the opportunity.

The market is nevertheless entering a more complex phase. Access, reimbursement, treatment persistence, supply capacity, safety monitoring, and competition from oral and next-generation therapies will increasingly determine how obesity medicines are used in real-world healthcare.

For pharmaceutical companies, Zepbound demonstrates the value of combining clinical differentiation with manufacturing scale and flexible commercialization. For payers and healthcare systems, it raises difficult questions about affordability and long-term value. For providers, it creates opportunities to integrate pharmacological obesity treatment into broader chronic disease management.

The next stage of the Zepbound market will therefore depend not simply on prescription volume, but on how effectively the healthcare system can support long-term, evidence-based, and financially sustainable use of obesity therapies.

Sources and References

• U.S. Food and Drug Administration (FDA), “FDA Approves New Medication for Chronic Weight Management,” November 2023.
• U.S. Food and Drug Administration (FDA), “FDA Approves First Medication for Obstructive Sleep Apnea,” December 2024.
• U.S. Food and Drug Administration, Zepbound (tirzepatide) Prescribing Information, revised August 2026.
• U.S. Food and Drug Administration, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize,” 2026.
• Centers for Medicare & Medicaid Services (CMS), “Medicare GLP-1 Bridge,” 2026.
• Centers for Medicare & Medicaid Services, “CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications,” July 2026.
• Eli Lilly and Company, Fourth-Quarter 2025 Financial Results and 2026 Guidance.
• Eli Lilly and Company, First-Quarter 2026 Financial Results.
• Eli Lilly and Company, Second-Quarter 2026 Financial Results.
• Eli Lilly and Company, “Zepbound: Most Prescribed Weight Management Medication in 2025, Now Available in Multi-Dose KwikPen,” 2026.
• Eli Lilly and Company, “Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy,” May 2026.
• Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” New England Journal of Medicine, 2025. 
• Malhotra A, et al. “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.” New England Journal of Medicine, 2024.
• Packer M, et al. “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine, 2025.
• Loomba R, et al. “Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis.” New England Journal of Medicine, 2024.
• ClinicalTrials.gov, SURMOUNT-MAINTAIN and SURMOUNT-MMO trial records.